Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Bullish +60

Jim Cramer on Bristol-Myers Squibb: “The Stock’s Recent Pullbacks Have Represented Terrific Buying Opportunities”

AI-generated analysis

📈 Jim Cramer recommends Bristol-Myers Squibb (BMY) as a top pick for the Charitable Trust he manages.

📉 The stock recently stalled after a strong 28% gain since late October but broke out above its 50-day moving average.

💰 BMY offers a solid 4.3% dividend yield, providing protection in a potential harsh economic slowdown.

🔬 The pharmaceutical company develops medicines for cancer, cardiovascular, immune, and neurological conditions.

💊 Key products include well-known drugs such as Eliquis, Opdivo, and Orencia.

📈 Analyst Lang sees the stock making a run to between $66 and $70 from its current level of $58.94.

🔍 Chaikin Money Flow metrics indicate that buying opportunities are strong despite recent pullbacks.

⚖️ Cramer views recent price drops as healthy corrections rather than signs of fundamental weakness.

🤝 The recommendation aligns with owning defensive stocks during economic uncertainty and higher energy costs.

❗ Insider Monkey notes that AI stocks may offer greater upside potential compared to BMY.

📰 Additional content links promote reports on short-term AI stocks and other high-performing equities.

Bullish Signals
  • Bristol-Myers Squibb (NYSE:BMY) is owned by the Charitable Trust, indicating strong institutional confidence in the stock.
  • The stock has already gained a quiet 28% since the end of October, demonstrating recent positive momentum.
  • Technical analysis shows the stock broke out above the 50-day moving average, signaling a potential continuation of the uptrend.
  • Chaikin Money Flow remains strong, suggesting sustained buying pressure into the current pullback.
  • The company offers a strong 4.3% dividend yield, providing attractive income protection even if economic conditions slow down.
  • Analyst Lang sees upside potential with price targets ranging from $66 to $70 against the current price of $58.94.
  • Bristol-Myers develops and sells key medicines for cancer, cardiovascular, immune, and neurological conditions, including well-known drugs like Eliquis, Opdivo, and Orencia.
Risk Factors
  • The stock has recently stalled after a massive run from November through February, indicating potential weakness following its prior rally.
  • Despite being up 28% since the end of October, Bristol-Myers Squibb (NYSE:BMY) is currently trading at $58.94 with a target range of $66 to $70 by Lang, which represents modest upside potential.
Full Analysis
Jim Cramer reviewed Bristol-Myers Squibb (NYSE:BMY) during a segment analyzing 16 stocks suitable for a market environment characterized by higher energy costs and economic uncertainty. Cramer highlighted that he owns the pharmaceutical company’s stock for the Charitable Trust, noting its significant performance over the past year. The stock experienced a substantial rally from November through February but recently stalled; however, it has still risen quietly 28% since late October. Cramer expressed surprise at recent technical activity as the stock broke out above its 50-day moving average after pulling back in recent weeks, a move analyst Lang attributes to a healthy correction rather than a trend change. Technical indicators and fundamentals continue to support Cramer’s bullish outlook on BMY. He pointed out that the Chaikin Money Flow remains strong, mirroring the behavior he observed with Merck, suggesting these pullbacks present excellent buying opportunities. Currently trading at $58.94, Bristol-Myers offers a robust 4.3% dividend yield. Analyst Lang sees potential for the stock to advance between $66 and $70, positioning it as an ideal holding if the market faces a harsh economic slowdown. Its high yield provides income protection, while the underlying business develops and sells medicines for cancer, cardiovascular, immune, and neurological conditions with well-known products including Eliquis, Opdivo, and Orencia. Despite acknowledging BMY's potential as an investment, the article contrasts it with emerging sectors like artificial intelligence. The author suggests that certain AI stocks may offer greater upside potential with less downside risk compared to traditional pharmaceutical giants. Furthermore, the content points to a separate free report focused on undervalued AI stocks that could benefit from Trump-era tariffs and the trend of onshoring, directing readers toward specific short-term investment opportunities in that space. The overall narrative positions BMY as a defensive stock for difficult economic times while simultaneously promoting higher-risk, high-reward AI alternatives for investors seeking aggressive growth.